gemcitabine has been researched along with Sarcopenia in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 7 (58.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ashida, R; Emori, T; Hatamaru, K; Itonaga, M; Kawai, M; Kawaji, Y; Kitano, M; Koike, M; Shimokawa, T; Sonomura, T; Tamura, T; Yamashita, Y | 1 |
| Asama, H; Fukushima, T; Kawano, K; Kobayashi, S; Maeda, S; Morimoto, M; Nagashima, S; Ohira, H; Sano, Y; Tanaka, S; Ueno, M | 1 |
| Iede, K; Ikenaga, M; Koh, M; Matsuyama, J; Nakashima, S; Ohta, K; Tanida, T; Tominaga, S; Tsuda, Y; Ueda, M; Yamada, T | 1 |
| Hasegawa, R; Imaizumi, H; Ishizaki, A; Ishizaki, J; Iwai, T; Kaneko, T; Kida, M; Kurosu, T; Kusano, C; Okuwaki, K; Watanabe, M; Yamauchi, H | 1 |
| Hikita, K; Honda, M; Iwamoto, H; Kimura, Y; Morizane, S; Nishikawa, R; Takenaka, A; Teraoka, S; Yumioka, T | 1 |
| Akita, H; Ando, R; Chaya, R; Etani, T; Iida, K; Kobayashi, D; Moritoki, Y; Nagai, T; Naiki, T; Nozaki, S; Okamura, T; Sugiyama, Y; Yanase, T; Yasui, T | 1 |
| Choi, MH; Hong, TH; Kim, IH; Lee, IS; Lee, MA | 1 |
| Furukawa, T; Kasuga, A; Matsuyama, M; Mie, T; Ozaka, M; Sasahira, N; Sasaki, T; Takeda, T; Yamada, Y | 1 |
| Abe, H; Kamai, T; Kobayashi, M; Mizuno, T; Nishihara, D; Nukui, A; Sakamoto, K; Suzuki, I; Takei, K; Tokura, Y; Uematsu, T; Yamaguchi, Y | 1 |
| Amundsen, T; Grønberg, BH; Helbostad, JL; Hjelde, H; Kaasa, S; Stene, GB; Sørhaug, S | 1 |
| Aloia, T; Balachandran, A; Conrad, C; Cooper, AB; Evans, DB; Fleming, JB; Fogelman, D; Garg, N; Holmes, HM; Katz, MH; Lee, JE; Ngo-Huang, A; Parker, N; Petzel, M; Slack, R; Varadhachary, G; Vauthey, JN | 1 |
| Boudou-Rouquette, P; Brezault, C; Chaussade, S; Coriat, R; Dhooge, M; Durand, JP; Goldwasser, F; Mir, O; Perkins, G; Ropert, S | 1 |
1 trial(s) available for gemcitabine and Sarcopenia
| Article | Year |
|---|---|
Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cachexia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Drug Dosage Calculations; Female; Gemcitabine; Humans; Lumbosacral Region; Lung Neoplasms; Male; Middle Aged; Muscle, Skeletal; Palliative Care; Pilot Projects; Radiography; Sarcopenia; Sex Factors; Vinblastine; Vinorelbine | 2015 |
11 other study(ies) available for gemcitabine and Sarcopenia
| Article | Year |
|---|---|
Impact of sarcopenia on prediction of progression-free survival and overall survival of patients with pancreatic ductal adenocarcinoma receiving first-line gemcitabine and nab-paclitaxel chemotherapy.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Sarcopenia | 2022 |
Sarcopenia: Prognostic Value for Unresectable Pancreatic Ductal Adenocarcinoma Patients Treated With Gemcitabine Plus Nab-Paclitaxel.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Sarcopenia | 2022 |
Baseline Factors Predictive of the Receipt of Second-Line Chemotherapy After Nab-Paclitaxel Plus Gemcitabine for Patients With Advanced Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Hypoalbuminemia; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Sarcopenia | 2022 |
Implication of Skeletal Muscle Loss in the Prognosis of Patients with Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Muscle, Skeletal; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Sarcopenia | 2023 |
Sarcopenia as a significant predictive factor of neutropenia and overall survival in urothelial carcinoma patients underwent gemcitabine and cisplatin or carboplatin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Retrospective Studies; Sarcopenia; Thrombocytopenia; Tomography, X-Ray Computed; Urologic Neoplasms | 2020 |
Skeletal Muscle Mass Reduction Velocity as a Simple Prognostic Indicator for Patients with Metastatic Urothelial Carcinoma Receiving Second-Line Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Muscle, Skeletal; Prognosis; Retrospective Studies; Sarcopenia; Survival Rate; Urologic Neoplasms | 2019 |
Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Muscle, Skeletal; Palliative Care; Pancreatic Neoplasms; Prognosis; Progression-Free Survival; Retrospective Studies; Sarcopenia; Tomography, X-Ray Computed | 2021 |
The impact of body composition on short-term outcomes of neoadjuvant chemotherapy with gemcitabine plus S-1 in patients with resectable pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Risk Factors; Sarcopenia; Tegafur; Treatment Outcome | 2021 |
Significance of sarcopenia as a prognostic factor for metastatic urothelial carcinoma patients treated with systemic chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Carboplatin; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Muscle, Skeletal; Prognosis; Retrospective Studies; Sarcopenia; Tomography, X-Ray Computed; Urologic Neoplasms | 2018 |
Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Body Weight; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Follow-Up Studies; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Sarcopenia; Survival Rate | 2015 |
Feasibility of gemcitabine and oxaliplatin in patients with advanced biliary tract carcinoma and a performance status of 2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma; Cholangitis; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Peripheral Nervous System Diseases; Retrospective Studies; Sarcopenia; Severity of Illness Index; Thrombocytopenia; Treatment Outcome | 2012 |